No. It means if it DOES double then he is cashing out and heading over to the Burger King for a Whopper and large fries with his profits.
At least 30 ID's. At least.
They were there the whole time. You can just find them now since you got rid of some of that flab.
Congrats... I guess. Not sure.
When you have a two day holiday at the END of one week, you have to consider that there is some lag between when scripts are written and when they are FILLED. MD's did not write scripts on Thursday and Friday of Thanksgiving week.
Those who put scripts in their pockets or purses to be filled the next time they are at Walmart or out shopping will likely fill the scripts 1-3 days after it was written.
So, the Thursday holiday likely took a big chunk out of Friday's fills, and even into the weekend. No new scripts would have been written on Friday too. That means a strong negative on the Saturday after Thanksgiving, bringing down last week's reports.
So, the week ending 12/13 will be the first truly 'full' week since Thanksgiving. There will be no lagging weakness as would have likely been seen in the 12/6 #'s.
Looks more like a deep pullback after a legitimate upside breakout. It is still above the 50 DMA and appears to have found some support there.
It is my understanding that stomach stapling does not necessarily reduce the appetite. It reduces the amount of food that can be physically digested. I recall that patients who have had their stomachs stapled are warned that overeating can lead to serious consequences.
I would think that Belviq would be a near perfect adjunct therapy to surgery to help ensure the patient's satiety level is reduced at the same time their capacity is.
I suspect that it was the interest rates that the markets liked even more...
And, just like the majority of the vacuum cleaners that CR tests, you don't even do a good job at sucking.
The old Reagan line about liberals would apply here...
"It's not that they don't know anything.... it's just that they know so much that isn't true."
Just to be sociable, that's not going to happen. If it did happen then ARNA should not have a market cap. But, major pharmaceutical companies are not in the habit of ponying up 120 million plus the lion's share of lorcaserin-related development and study costs going forward if the outcome is for sales to plateau less than a year into the marketing of it.
Just to be sociable, what would happen if sales kept growing at 3% WoW on average for the next 3 years instead of hitting your imaginary ceiling of 10,000/week? That would be over 500,000 weekly scripts in three years. That would be 1.2 billion in revenue to ARNA for 2017. Give it a modest PE of 10 and that is a share price of 55 bucks. And that's got nothing to do with Mexico, Taiwan, Brazil, smoking cessation, Bel-Phen, or anything else in the pipeline.
You may be looking at JAZZ v2.0 here.
Hey... I got an idea.
Go drink about 12 beers and then clean your guns.